Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations

References

• Those 2012 data are based on the Global Observatory on Donation and Transplantation (GODT) data, produced by the WHO-ONT collaboration
   Google Scholar
• Available from: http://optn.transplant.hrsa.gov/latestData/rptData.asp [Accessed 3 June 2014]
   Google Scholar
• Available from: http://optn.transplant.hrsa.gov/latestData/rptData.asp Data as of June 27, 2014 [Accessed 2 July 2014]
   Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
   PubMed Web of Science ®Google Scholar
• Colombo D, Ammirati E. Cyclosporine in transplantation - a history of converging timelines. J Biol Regul Homeost Agents 2011;25:493-504
   PubMed Web of Science ®Google Scholar
• Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004;36:13S-5S
   PubMed Web of Science ®Google Scholar
• Prograf, prescribing information. Astellas Pharma US, Inc; Northbrook, IL: 2013
   Google Scholar
• Advagraf 0.5 mg, 1 mg, 3 mg and 5 mg tacrolimus extended release capsules. Product Monograph. Astellas Pharma Canada, Inc. Markham, ON. 2010; Northbrook, IL
   Google Scholar
• ASTAGRAF XL - tacrolimus capsule, coated, extended release. Astellas Pharma US, Inc; Northbrook, IL: 2014)
   Google Scholar
• Webster AC, Taylor RRS, Chapman JR, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;19(4):CD003961
   Google Scholar
• Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2012 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration; Rockville, MD: 2014
   Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-157
   PubMed Web of Science ®Google Scholar
• Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM181006.pdf
   Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53
   PubMed Web of Science ®Google Scholar
• Provenzani A, Santeusanio A, Mathis E, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013;19:9156-73
   PubMed Web of Science ®Google Scholar
• Abouljoud MS, Kumar MSA, Brayman KL, et al. Neoral® rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002;16:168-72
   PubMed Web of Science ®Google Scholar
• Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13:313-26
   PubMed Web of Science ®Google Scholar
• Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991;23:3175-8
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Hutcherson T, Preston D, et al. Influence of pill burden and drug cost on renal function after transplantation. Pharmacotherapy 2012;32:427-32
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Tielen M, van Exel J, Laging M, et al. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant 2014;2014:675301
   PubMedGoogle Scholar
• Morrissey PE, Reinert S, Yango A, et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. Transplant Proc 2005;37:2044-7
   PubMed Web of Science ®Google Scholar
• Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004;4:1509-13
   PubMed Web of Science ®Google Scholar
• Michelon T, Dominguez V, Losekan A, et al. Kidney graft failure due to noncompliance. Transplant Proc 1999;31:3031-2
   PubMed Web of Science ®Google Scholar
• Jarzembowski T, John E, Panaro F, et al. Impact of non-compliance on outcome after pediatric kidney transplantation: an analysis in racial subgroups. Pediatr Transplant 2004;8:367-71
   PubMed Web of Science ®Google Scholar
• Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004;77:769-76
   PubMed Web of Science ®Google Scholar
• Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009;9:2505-13
   PubMed Web of Science ®Google Scholar
• Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010;10:2632-43
   PubMed Web of Science ®Google Scholar
• Silva HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007;7:595-608
   PubMed Web of Science ®Google Scholar
• Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 2012;94:1013-19
   PubMed Web of Science ®Google Scholar
• Rath T. Tacrolimus in transplant rejection. Expert Opin Pharmacother 2013;14:115-22
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
   PubMed Web of Science ®Google Scholar
• MeltDose® Technology by the US Patent and Trademark Office. US7217431
   Google Scholar
• Nigro V, Glicklich A, Weinberg J. Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation [abstract B1034]. American Transplant Congress, 2013
   Google Scholar
• Gaber AO, Alloway RR, Bodziak K, et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 2013;96:191-7
   PubMed Web of Science ®Google Scholar
• Holm P, Thomassen JQ, Rasmussen SR. MeltDose® a one step industrial process for the manufacturing of solid dispersion. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 7th to 10th April 2008; CCIB, Barcelona, Spain
   Google Scholar
• Buch P, Holm P, Thomassen JQ, et al. IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics. J Pharm Sci 2010;99(10):4427-36
   PubMed Web of Science ®Google Scholar
• Advagraf. European public assessment report (EPAR). Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000712/human_med_000629.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Vicari-Christensen M, Repper S, Basile S, et al. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners’ understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009;19:277-84
   PubMed Web of Science ®Google Scholar
• Available from: www.drugbank.ca/drugs/DB00864
   Google Scholar
• Gavhanea YN, Yadavb AV. Loss of orally administered drugs in GI tract. Saudi Pharm J 2012;20:331-44
   PubMed Web of Science ®Google Scholar
• Thörn M, Finnström N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60
   PubMed Web of Science ®Google Scholar
• Alloway RR, Eckhoff DE, Washburn WK, et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): phase II trial of stable liver transplant recipients. Liver Transpl 2014;20:564-75
   PubMed Web of Science ®Google Scholar
• EMEA. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products; London: 1999
   Google Scholar
• Feng S, Chapman WC, DuBay D. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twice-a-day in de novo liver transplants [abstract 709]. Presented at the 2012 American Transplant Congress; 2–6 June 2012; Boston, Massachusetts
   Google Scholar
• Budde K, Bunnapradist S, Grinyo JM, et al. Once daily LCP-Tacro MeltDose® tacrolimus vs. twice daily tacrolimus in de novo kidney transplants: one-year results of Phase 3, double-blind, randomized trial. Am J Transplant 2014; In press
   Google Scholar
• CellCept, (mycophenolate mofetil) summary of product characteristics (SPC, SmPC)
   Google Scholar
• Myfortic, (mycophenolate acid) summary of product characteristics (SPC, SmPC)
   Google Scholar
• Nigro V, Glicklich A, Weinberg J. Flexible dosing of once-daily LCP-Tacro tablets: morning vs. evening randomized crossover chronopharmacokinetic study. AST/ESOT Joint Meeting; 12–14 October 2012; Nice, France
   Google Scholar
• Barraclough K, Isbel N, Johnson D, et al. Once-versus twice-daily tacrolimus. Drugs 2011;71:1561-77
   PubMed Web of Science ®Google Scholar
• Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011;91:566-9
   PubMed Web of Science ®Google Scholar
• Gabardi S, Nigro V, Johnson J, et al. Evaluation of steady–state pharmacokinetic parameters of LCP-Tacro™and Advagraf® in healthy volunteers using a systems dynamic model [abstract 2308787]. Poster presented at the European Society of Transplantation. Vienna, 2013
   Google Scholar
• Bunnapradist S, Alloway R, West-Thielke P, et al. Lower treatment failures in blacks and older denovo and stable kidney transplant recipients treated with envarsus once-daily meltdose tablets vs. twice-daily prograf capsules: a pooled subgroup analysis of two phase 3 trials [abstract# 50]. World Transplant Congress (WTC); 26-31 July 2014; San Francisco, California
   Google Scholar
• Alloway R, Mulgaonkar S, Ueda K, et al. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-tacro tablets once-a-day vs prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant 2011;11:355
   Web of Science ®Google Scholar
• Mulgaonkar S, Alloway RR. LCP-Tacro demonstrated significantly fewer dose adjustments: results of a phase 2 randomized study of lcp-tacro (meltdose once-daily prolonged release tacrolimus tablets) vs. prograf® capsules twice-a-day in de novo kidney transplant patients [abstract 51]. The European Society for Organ Transplantation (ESOT) and the American Society of Transplantation (AST); 17–19 October 2014; Madrid, Spain; 2014
   Google Scholar
• Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013;13:760-9
   PubMed Web of Science ®Google Scholar
• Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation 2013;96:897-903
   PubMed Web of Science ®Google Scholar
• Grinyo JM, Rostaing L, Budde K, et al. Rapid attainment of tacrolimus trough levels early post-transplant reduces risk of treatment failure in de novo kidney transplant patients: a covariate analysis of a phase 3 double-blind study [abstract #1571]. World Transplant Congress; 26–31 July 2014; San Francisco, CA; 2014
   Google Scholar
• Paul LC. Overview of side effects of immunosuppressive therapy. Transplant Proc 2001;33:2089
   PubMed Web of Science ®Google Scholar
• Gedaly R, Steinberg SM, Langone A, et al. LCP-Tacro–associated improvement in tacrolimus–induced tremors is also associated with improvement in quality of life: results of a switching study of kidney transplant patients with tremor (strato). European Society for Transplantation (ESOT); 2013
   Google Scholar